{
    "name": "tetanus immune globulin (TIG)",
    "comment": "Rx",
    "other_names": [
        "Hyper Tet",
        "HyperTET S/D",
        "TIG"
    ],
    "classes": [
        "Immune Globulins"
    ],
    "source": "https://reference.medscape.com/drug/hypertet-s-d-tetanus-immune-globulin-tig-343144",
    "pregnancy": {
        "common": [
            "Pregnancy Category: C",
            "Lactation: not known if excreted in breast milk, no adverse effects reported"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Lactation: not known if excreted in breast milk, no adverse effects reported"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to gamma globulin, IgA, thimerosal"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Thrombocytopenia or coagulation disorders may contraindicate IM injection",
                "Made from human plasma, small risk of viral transmission through administration"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "axicabtagene ciloleucel",
            "description": {
                "common": "tetanus immune globulin (TIG), axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "brexucabtagene autoleucel",
            "description": {
                "common": "tetanus immune globulin (TIG), brexucabtagene autoleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ciltacabtagene autoleucel",
            "description": {
                "common": "tetanus immune globulin (TIG), ciltacabtagene autoleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "idecabtagene vicleucel",
            "description": {
                "common": "tetanus immune globulin (TIG), idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lisocabtagene maraleucel",
            "description": {
                "common": "tetanus immune globulin (TIG), lisocabtagene maraleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tisagenlecleucel",
            "description": {
                "common": "tetanus immune globulin (TIG), tisagenlecleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "adenovirus types 4 and 7 live, oral",
            "description": {
                "common": "tetanus immune globulin (TIG) decreases effects of adenovirus types 4 and 7 live, oral by pharmacodynamic antagonism. Use Caution/Monitor. Separate by 3 months."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "BCG vaccine live",
            "description": {
                "common": "tetanus immune globulin (TIG) decreases effects of BCG vaccine live by pharmacodynamic antagonism. Use Caution/Monitor. Separate by 3 months."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "efgartigimod alfa",
            "description": {
                "common": "efgartigimod alfa will decrease the level or effect of tetanus immune globulin (TIG) by  receptor binding competition. Use Caution/Monitor. Coadministration of efgartigimod with medications that bind to the human neonatal Fc receptor may lower systemic exposures and effectiveness of such medications. Closely monitor for reduced effectiveness of medications that bind to the human neonatal Fc receptor. If long-term use of such medications is essential, consider discontinuing efgartigimod and using alternative therapies."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "measles (rubeola) vaccine",
            "description": {
                "common": "tetanus immune globulin (TIG) decreases effects of measles (rubeola) vaccine by pharmacodynamic antagonism. Use Caution/Monitor. Separate by 3 months."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "measles mumps and rubella vaccine, live",
            "description": {
                "common": "tetanus immune globulin (TIG) decreases effects of measles mumps and rubella vaccine, live by pharmacodynamic antagonism. Use Caution/Monitor. Separate by 3 months."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "measles, mumps, rubella and varicella vaccine, live",
            "description": {
                "common": "tetanus immune globulin (TIG) decreases effects of measles, mumps, rubella and varicella vaccine, live by pharmacodynamic antagonism. Use Caution/Monitor. Separate by 3 months."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rubella vaccine",
            "description": {
                "common": "tetanus immune globulin (TIG) decreases effects of rubella vaccine by pharmacodynamic antagonism. Use Caution/Monitor. Separate by 3 months."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "smallpox (vaccinia) vaccine, live",
            "description": {
                "common": "tetanus immune globulin (TIG) decreases effects of smallpox (vaccinia) vaccine, live by pharmacodynamic antagonism. Use Caution/Monitor. Separate by 3 months."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "varicella virus vaccine live",
            "description": {
                "common": "tetanus immune globulin (TIG) decreases effects of varicella virus vaccine live by pharmacodynamic antagonism. Use Caution/Monitor. Separate by 3 months."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "protein a column",
            "description": {
                "common": "protein a column decreases levels of tetanus immune globulin (TIG) by Other (see comment). Minor/Significance Unknown. \nComment: Since Prosorba binds IgG, it could theoretically interfere with the levels and/or effects of pharmacologic immune globulins."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Urticaria",
            "percent": null
        },
        {
            "name": "Injection site pain",
            "percent": null
        },
        {
            "name": "N",
            "percent": null
        },
        {
            "name": "V",
            "percent": null
        },
        {
            "name": "Fever",
            "percent": null
        },
        {
            "name": "Lethargy",
            "percent": null
        },
        {
            "name": "Chest tightness",
            "percent": null
        },
        {
            "name": "Anaphylaxis",
            "percent": null
        },
        {
            "name": "Angioneurotic edema",
            "percent": null
        },
        {
            "name": "Nephrotic syndrome",
            "percent": null
        },
        {
            "name": "rare",
            "percent": null
        }
    ]
}